University of Louisville
Latest From University of Louisville
Bayer will collaborate with start-up Hope Medicine to develop antibody therapies targeting the PRL receptor. WARF and Sanford Burnham Prebys partner on translational research.
Private Company Edition: General Partner Clay Thorp says the venture capital firm's longtime focus on seed and early-stage investments is unchanged and bolstered by market fundamentals. Also, Talaris and insitro each raised $100m Series A rounds, plus other financings.
Asterias obtains IP estate related to ischemic stroke from University of California. Plus Apeiron, Qualigen, Biovaxys and AbbVie turn to academic partners for early-stage cancer assets.
NeuroRecovery Technologies Inc. has developed both an implantable and external spinal cord stimulator to restore functional capacity that has been lost due to paralysis. The company’s neuromodulation technology is applied below the anatomical level of the injury to tap healthy nerve fibers ready to be activated, re-establishing connectivity and enabling motor response in paralyzed muscles.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.